financetom
Business
financetom
/
Business
/
BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates
Mar 11, 2026 6:45 AM

BrainsWay Ltd. ( BWAY ) reported fourth-quarter financial results on Wednesday ahead of the market open.BrainsWay Ltd. ( BWAY ) reported fourth-quarter financial results on Wednesday ahead of the market open. Here’s a look at the key details from the report.

BrainsWay ( BWAY ) stock is trending lower. Why is BWAY stock falling?

Q4 Financial Results

BrainsWay ( BWAY ) reported earnings per share of 4 cents, inline with the consensus estimate. In addition, it reported revenue of $14.54 million, beating the consensus estimate of $14.01 million and representing a 27% year-over-year increase.

The company shipped a net total of 95 Deep TMS systems during the fourth quarter, a 27% increase from the same period last year, bringing the total installed base to approximately 1,700 systems.

BrainsWay ( BWAY ) said remaining performance obligations increased 43% to approximately $70 million.

"Demand for Deep TMS continues to accelerate, supported by expanding customer adoption, additional regulatory clearances, and growing reimbursement coverage," said CEO Hadar Levy.

The U.S. Food and Drug Administration (FDA) granted label expansion for Deep TMS system, making the treatment available as an adjunct therapy for adolescents aged 15 to 21 years suffering from major depressive disorder (MDD).

Looking ahead, the company expects fiscal-year revenue of $51.00 million to $52.00 million, versus the consensus estimate of $64.98 million.

BrainsWay Shares Edge Lower

BWAY Price Action: At the time of publication, BrainsWay ( BWAY ) shares are trading 2.68% lower at $13.05, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Currenc's Chief Executive Ronnie Hui Steps Down; Founder Alex Kong to Reassume Role
Currenc's Chief Executive Ronnie Hui Steps Down; Founder Alex Kong to Reassume Role
Aug 15, 2025
09:50 AM EDT, 08/15/2025 (MT Newswires) -- Currenc ( CURR ) said Friday Ronnie Hui has stepped down from his role as chief executive. Founder and executive chairman Alex Kong will take over as CEO, a role he has previously held, the company said. Shares of the company were flat in early Friday trading. Price: 1.67, Change: -0.04, Percent Change:...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Update: Roblox Sued by Louisiana on Allegations of Child Safety Failures; Shares Fall Pre-Bell
Update: Roblox Sued by Louisiana on Allegations of Child Safety Failures; Shares Fall Pre-Bell
Aug 15, 2025
09:47 AM EDT, 08/15/2025 (MT Newswires) -- (Updates with Roblox's ( RBLX ) response in the fifth paragraph) Roblox ( RBLX ) is being sued by Louisiana on accusations that the gaming platform fails to enforce safety controls to protect children and facilitates the distribution of child sexual material, a statement from state attorney general Liz Murrill's office showed. The...
Why Is Precigen Stock Surging On Friday?
Why Is Precigen Stock Surging On Friday?
Aug 15, 2025
On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.’s Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP). RRP is a rare chronic disease caused by the human papillomavirus (HPV) and wart-like tumors grow on and around the vocal cords. Papzimeos is the first and only FDA-approved therapy for the treatment of adults with RRP. Precigen (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved